BRCA1 and pancreatic neoplasm: Interestingly, as patients with a family history (within the third degree) of metastatic prostatic or pancreatic cancer were included in the expanded insurance criteria, the number of BRCA1/2 mutation tests carried out on these patients increased dramatically from 0.4% before the Korean NIC expansion to 8.9% after the Korean NIC expansion and remained about the same (7.4%) after additional genetic counselor involvement.